Systematic review and meta-analysis shows UV-C effectively inactivates viruses, indicating important applications for public health.
This study evaluates fragmented data on ultraviolet-C (UV-C, 100–280 nm) irradiation for viral inactivation in liquid media, supporting advances such as whole-pathogen vaccine development and downstream research. Included studies reported viral strain identification, baseline titers (PFU or TCID50), UV-C wavelength, dosage, and log reductions, excluding studies employing alternative treatments. We searched (PubMed, Ovid Medline, Scopus, Embase, Web of Science; 10 April 2024) and identified 2813 records, of which 33 met the inclusion criteria. Risk of bias was assessed using ROBINS-I V2 to evaluate methodological rigor and inform improved reporting. Narrative synthesis summarized findings across viruses, while meta-analysis focused on 16 SARS-CoV-2 studies with standardized reporting. Meta-regression revealed a strong dose–response relationship (log_dose β = 3.38, 95% CI [2.95, 3.82], p < 0.001) with low heterogeneity (I2 = 15.1%). Strain and wavelength-specific efficacy peaked at 267 nm (β = 6.42) and 275 nm (β = 3.78), while 253.7 nm offered structural preservation for downstream applications. Limitations included inconsistent dose reporting, matrix effects, and assay sensitivity. We propose a refined reporting framework and standard definitions for ‘inactivation’, ‘‘disinfection,’ and ‘complete inactivation.’ Our findings support reproducible UV-C evaluation, regulatory alignment, and safe implementation in pathogen control, biosafety, and clinical applications.
No takes yet. Share an insight, caveat, or question.
Hetényi et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: